JP2011527666A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527666A5
JP2011527666A5 JP2011507512A JP2011507512A JP2011527666A5 JP 2011527666 A5 JP2011527666 A5 JP 2011527666A5 JP 2011507512 A JP2011507512 A JP 2011507512A JP 2011507512 A JP2011507512 A JP 2011507512A JP 2011527666 A5 JP2011527666 A5 JP 2011527666A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound according
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011507512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527666A (ja
JP5442717B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/039065 external-priority patent/WO2009134574A2/en
Publication of JP2011527666A publication Critical patent/JP2011527666A/ja
Publication of JP2011527666A5 publication Critical patent/JP2011527666A5/ja
Application granted granted Critical
Publication of JP5442717B2 publication Critical patent/JP5442717B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011507512A 2008-04-29 2009-04-01 二置換フタラジンヘッジホッグ経路アンタゴニスト Expired - Fee Related JP5442717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29
US61/048,729 2008-04-29
PCT/US2009/039065 WO2009134574A2 (en) 2008-04-29 2009-04-01 Disubstituted phthalazine hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2011527666A JP2011527666A (ja) 2011-11-04
JP2011527666A5 true JP2011527666A5 (https=) 2013-05-23
JP5442717B2 JP5442717B2 (ja) 2014-03-12

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507512A Expired - Fee Related JP5442717B2 (ja) 2008-04-29 2009-04-01 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (22)

Country Link
US (1) US7981892B2 (https=)
EP (1) EP2294061A2 (https=)
JP (1) JP5442717B2 (https=)
KR (1) KR101260116B1 (https=)
CN (1) CN102066353B (https=)
AU (1) AU2009241561B2 (https=)
BR (1) BRPI0911618A2 (https=)
CA (1) CA2723042A1 (https=)
CO (1) CO6300945A2 (https=)
CR (1) CR11741A (https=)
DO (1) DOP2010000302A (https=)
EA (1) EA201071248A1 (https=)
EC (1) ECSP10010577A (https=)
HN (1) HN2010002157A (https=)
IL (1) IL208211A0 (https=)
MA (1) MA32349B1 (https=)
MX (1) MX2010011948A (https=)
MY (1) MY159491A (https=)
NZ (1) NZ588001A (https=)
UA (1) UA102250C2 (https=)
WO (1) WO2009134574A2 (https=)
ZA (1) ZA201006695B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
MX2011004683A (es) 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
KR20120107962A (ko) * 2009-11-18 2012-10-04 노파르티스 아게 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
WO2014043608A2 (en) * 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
IL319619A (en) * 2022-09-23 2025-05-01 Merck Sharp & Dohme Llc Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
MY117098A (en) * 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
ES2377430T3 (es) 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MX2011004683A (es) 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2011527666A5 (https=)
JP2012530705A5 (https=)
JP2012509265A5 (https=)
JP2012507535A5 (https=)
JP2010523692A5 (https=)
JP2010518090A5 (https=)
JP2014507464A5 (https=)
JP2012509263A5 (https=)
JP2010526814A5 (https=)
JP2014508811A5 (https=)
JP2014504646A5 (https=)
JP2009535462A5 (https=)
JP2010523670A5 (https=)
JP2009263394A5 (https=)
JP2009515988A5 (https=)
CN109661394A (zh) Fgfr4抑制剂、其制备方法与药学上的应用
JP2010520214A5 (https=)
JP2008044952A5 (https=)
JP2013502441A5 (https=)
JP2009149903A5 (https=)
JP2013522292A5 (https=)
JP2014528403A5 (https=)
JP2011529054A5 (https=)
JP2017528475A5 (https=)
JP2010511721A5 (https=)